The recent development of several new, non-peptide, orally active angiotensin II
receptor antagonists is revolutionizing the treatment of patients with hypertension and
various cardiovascular disorders. In this book experts review the current state of
angiotensin II antagonists and survey the progress of these diverse applications. Issues
relating to angiotensin II and their receptors are examined in relation to their effects on
the kidney, non-diabetic renal disease, heart disease, diabetes mellitus, and various
other disorders. The combination of AT1 receptor antagonists with other
antihypertensive agents is reviewed in depth. The clinical attributes of these drugs are
complemented by in-depth reviews of the physiology and pharmacology of angiotensin
II peptides. The authors present the most recent findings in ligand recognition,
activation, signal coupling, desensitization and functional alterations of vessels,
especially small arteries, in patients with hypertension.

• This book constitutes the only available compendium on the clinical and experimental

features of angiotensin II receptor antagonists.

• The unique features of the rapidly emerging class of drugs are surveyed throughout.

Contributions have been made from international experts who have personally contributed to the discovery and development of these novel drugs.

• Recent cutting-edge physiology and pharmacology studies by renowned international experts provide a platform for considering the clinical applications of these agents.